ALECENSA

This brand name is authorized in Austria, Australia, Brazil, Cyprus, Ecuador, Estonia, Spain, Finland, France, Hong Kong, Croatia, Ireland, Israel, Japan, Lithuania, Netherlands, New Zealand, Poland, Romania, Singapore, Tunisia, Turkey, United Kingdom, United States, South Africa

Active ingredients

The drug ALECENSA contains one active pharmaceutical ingredient (API):

1 Alectinib
UNII P9YY73LO6J - ALECTINIB HYDROCHLORIDE

Alectinib is a highly selective and potent ALK and rearranged during transfection (RET) tyrosine kinase inhibitor. In pre-clinical studies, inhibition of ALK tyrosine kinase activity led to blockage of downstream signalling pathways including signal transducer and activator of transcription 3 (STAT 3) and phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT) and induction of tumour cell death (apoptosis).

Read about Alectinib

Medication package inserts

Below package inserts are available for further reading:

Title Information Source Document Type  
ALECENSA Hard capsule European Medicines Agency (EU) MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code Group title Classification
L01ED03 L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01E Protein kinase inhibitors → L01ED Anaplastic lymphoma kinase (ALK) inhibitors
Discover more medicines within L01ED03

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
Country: AU Pharmaceutical Benefits Scheme Identifier(s): 11226W
Country: BR Câmara de Regulação do Mercado de Medicamentos Identifier(s): 529219040027601
Country: EC Agencia Nacional de Regulación, Control y Vigilancia Sanitaria Identifier(s): 4434-MEE-1018
Country: EE Ravimiamet Identifier(s): 1739437, 1758708
Country: ES Centro de información online de medicamentos de la AEMPS Identifier(s): 1161169001
Country: FI Lääkealan turvallisuus- ja kehittämiskeskus Identifier(s): 474675
Country: FR Base de données publique des médicaments Identifier(s): 60639892
Country: GB Medicines & Healthcare Products Regulatory Agency Identifier(s): 341980, 383718
Country: HK Department of Health Drug Office Identifier(s): 64854
Country: IE Health Products Regulatory Authority Identifier(s): 88867
Country: IL מִשְׂרַד הַבְּרִיאוּת Identifier(s): 7799
Country: JP 医薬品医療機器総合機構 Identifier(s): 4291032M3021
Country: LT Valstybinė vaistų kontrolės tarnyba Identifier(s): 1082317, 1088944
Country: NL Z-Index G-Standaard, PRK Identifier(s): 141844
Country: NZ Medicines and Medical Devices Safety Authority Identifier(s): 19002
Country: PL Rejestru Produktów Leczniczych Identifier(s): 100383860
Country: RO Agenția Națională a Medicamentului și a Dispozitivelor Medicale Identifier(s): W64294001
Country: SG Health Sciences Authority Identifier(s): 15220P
Country: TN Direction de la Pharmacie et du Médicament Identifier(s): 6993241H
Country: TR İlaç ve Tıbbi Cihaz Kurumu Identifier(s): 8699505153407
Country: US FDA, National Drug Code Identifier(s): 50242-130
Country: ZA Health Products Regulatory Authority Identifier(s): 53/32.16/0183

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.